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Dear Editor,
Cyclin-dependent kinase 4 (CDK4) is a key protein in G1 transition during cell-cycle
progression [1]. Two different groups have postulated that CDK4 may be considered a
pancreatic tumor marker. These groups have not detected CDK4 expression in healthy
pancreas, but they have detected CDK4 in pancreatic endocrine tumors [2], intraepithelial
neoplasia and ductal adenocarcinoma of the pancreas [3]. These results clearly contrast with
those obtained from murine models, in which CDK4 is the main G1 transition kinase in the
pancreatic tissue. CDK4-null mice exhibit severe beta-cell mass hypoplasia, whereas islet
CDK4 hyperactivity induces hyperplasia without causing hypoglycemia [4]. The
explanation for this divergence was discussed at a symposium [5], where cyclin-dependent
kinase 6 (CDK6) was proposed as the protein responsible for regulating G1 transition in the
healthy pancreas of humans because only CDK6, not CDK4, has been detected in healthy
pancreases. However, in a subsequent study, these authors suggested that healthy isolated
human pancreatic islets express CDK6 and CDK4 [6].
To assess the usefulness of CDK4 as a biomarker of pancreatic cancer, we extensively
examined its presence using several techniques in normal pancreas (n=24) and islets (n=11),
pancreatic adenocarcinomas (n=125) and pancreatic neuroendocrine tumors (n=5). The
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detailed material and methods in the supplementary information are available at
https://sites.google.com/site/conchimoralabs/cdk4-pancreas-supplementary-information.
To observe the presence of CDK4 using immunohistochemistry, we used two similar
antibodies against CDK4 (H-22 and C-22; Santa Cruz Technology, Santa Cruz, CA, USA),
which were raised against the human or mouse C-terminal portion of CDK4, respectively. It
is noteworthy that one of the research groups mentioned above failed to detect CDK4 by
immunohistochemistry and western blot analysis in healthy human pancreas using the H-22
antibody [2]. We obtained similar results with both antibodies (see representative images in
Fig. 1, A-H) and observed that 58% of the healthy samples (14 of 24), 67% of the
adenocarcinomas (84 of 125) and 80% of the neuroendocrine tumors (4 of 5) were positive
for CDK4 staining (detailed results are available in the supplementary information). To
ensure staining specificity, we performed several quality controls. First, some human
pancreatic sections were stained only with the secondary antibodies, which did not produce
any staining signals. Second, Cdk4 staining of murine pancreatic sections showed a clear
nuclear staining in the endocrine and exocrine pancreatic tissue. Third, pancreatic tissue
sections of Cdk4-deficient mice were immunonegative for Cdk4 after the sections were
incubated with the anti-Cdk4 antibody. Finally, CDK4 staining in human samples that were
blocked with the CDK4-blocking peptide (Santa Cruz Technology) showed no signal. After
performing all of these controls (representative images are available in the supplementary
information), we concluded that the staining observed using the anti-CDK4 antibody in
human pancreatic sections was specific.
The lack of homogeneity in healthy pancreatic tissue -only 58% of the human healthy
pancreatic samples showed CDK4 staining- may be caused by the expected heterogeneity
within the human species or differences in processing of samples before performing the
immunohistochemistry technique (time before organ extraction, fixation time, etc.), which
remains to be explored in depth.
We evaluated the presence of CDK4 in human healthy islets using real-time PCR and
western blot analysis (Fig. 1, I-L). The presence of CDK4 was detected using western blot
analysis with four different anti-CDK4 antibodies: DCS-31 (Sigma, St. Louis, MO, USA),
DCS-156 (Becton Dickinson, Franklin Lakes, NJ, USA), C-22 and H-22 (Santa Cruz
Technology). To ensure the specificity of the results, we performed several quality controls.
First, we observed a clear western blot band using mouse pancreas lysates. Second, this band
was not present in the lysates of the Cdk4 knockout mouse pancreas. Third, the incubation
of the antibody with the corresponding blocking peptide did not render any signal in human
healthy islets (representative images are available in the supplementary information).
The role of CDK4 in cell-cycle progression has been clearly demonstrated [1]. Therefore,
we co-stained for CDK4 and the proliferation marker Ki-67. We found no correlation
between Ki-67 and CDK4 staining. These results suggest that the sole presence of CDK4 is
not indicative of proliferation (Fig. 1, M-X),
All of these results indicate that CDK4 is not useful as a tumor marker. We showed that
many healthy pancreatic samples were positive for this protein using different techniques.
Moreover, the in-depth analysis of the immunohistochemistry results from the SEER array
(Surveillance Epidemiology and End Results (SEER) Residual Tissue Repository tissue
array (Bethesda, MD, USA) [7]) reveal that, after adjusting for demographic and clinical
attributes, the survival analysis for 50 cases of pancreatic ductal adenocarcinoma-resection
tumors (41 cases with nuclear CDK4 staining versus 9 cases without nuclear CDK4
staining), showed a marginally improved survival time for the cases that exhibited nuclear
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CDK4 staining versus those that did not (log-rank test, p=0.016; hazard ratio, 2.2; 95%
confidence interval, 1.0–4.8).
In conclusion, our results suggest that the presence of CDK4 alone cannot be used as a
pancreatic tumor marker to distinguish between normal and tumor pancreas. In addition, we
hypothesize that the role of CDK4 in pancreatic tissue may extend beyond cell-cycle
progression, as CDK4 is also involved in other processes as the regulation of insulin
secretion in beta-cells [8].
Yours sincerely,
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Top Panels (A-H). Two representative sections of healthy human pancreas from the UTIP
healthy series (A-H) immunostained for CDK4 (A, E) and co-stained with insulin (B, F) and
the nuclear marker Hoechst (Sigma) (C, G) for nuclear detection. Each row corresponds,
from left to right, to the same section that was stained for CDK4 using the C-22 antibody
(A) or the H-22 antibody (E) in red (Cy3), insulin in green (B, F) (Cy2) and nuclear staining
with Hoechst in blue (C, G). The images were then merged (D, H). Images are at 40×
magnification using an epifluorescence microscope. Middle panels (I-L). Real-time PCR (I,
J) and western blot analysis (K, L) for CDK4 in human islets. I: Graphic representation of
the fluorescence vs. the cycles of real-time PCR for CDK4 for 8 different samples of human
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islets (in triplicate) and a negative control (no sample, plain line, in duplicate). J:
Quantification of the intensity that was obtained using real-time PCR and normalized to a
housekeeping gene (TBP). K: Representative western blots of CDK4 (C-22 antibody) and
beta-actin in human islets. L: Representative western blots of CDK4, which was performed
with the H-22 antibody, the DCS-31 antibody or the DCS-156 antibody, and beta-actin in
human islets. Bottom panels (M-X). Representative CDK4-positive cores from the PAC481
array showing a healthy human pancreas (M-P) and two different adenocarcinoma cores (Q-
T, U-X). From left to right, images of the same section that were stained for CDK4 (C-22
antibody) in red (Cy3), the proliferation marker Ki-67 in green (Cy2), nuclear staining with
Hoechst in blue, and a merge of all images are shown. An arrow indicates a CDK4- and
Ki-67-positive nucleus, a white arrowhead indicates a CDK4-positive and Ki-67-negative
nucleus, and a black arrowhead indicates a CDK4-negative and Ki-67-positive nucleus.
Images were taken at 40× magnification using a confocal microscope.
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